{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000015","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.818979+00:00","generated_at":"2026-06-16T07:59:02.867654+00:00","sec_items":["1.01","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lexicon shareholders approve amendment to increase equity plan shares to 55M","bullets":["Stockholders approved amendment to 2017 Equity Incentive Plan, increasing authorized shares from 30,000,000 to 55,000,000.","Amendment to 2017 Non-Employee Directors' Equity Incentive Plan increased share reserve from 1,200,000 to 2,000,000.","Voting results: For: 110,232,367; Against: 24,746,403; Abstain: 16,261,356; Broker non-votes: 13,664,122.","Amendments adopted by Board on Feb 9, 2023 and approved at annual meeting on April 27, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000015","json":"https://secwatch.observer/filing/0001062822-23-000015.json","markdown":"https://secwatch.observer/filing/0001062822-23-000015.md","text":"https://secwatch.observer/filing/0001062822-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/lxrx-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T07:59:02.867654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"090e7c94f043e0c52f616cafe0b8ae71af89ff5e","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Advisory vote to determine the frequency of future advisory votes on the compensation paid to our named executive officers at the 2023-04-27 meeting.","evidence_excerpt":"Advisory vote to determine the frequency of future advisory votes on the compensation paid to our named executive officers 133,664,598 143,970 949,241 16,482,317","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"2ebd18145a09f31434a5ebc641ab2aa897bccfb7","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Election of Class II Directors at the 2023-04-27 meeting.","evidence_excerpt":"Election of Class II Directors Name of Director For Withheld Broker Non-Votes Samuel L. Barker, Ph.D. 142,120,279 9,119,847 13,664,122 Christopher J. Sobecki 143,104,310 8,135,816 13,664,122 Judith L. Swain, M.D. 135,882,215 15,357,911 13,664,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"533289f2d1999f6521136c111dcb93c2d5ceb487","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the amendment to the Company’s 2017 Non-Employee Directors’ Equity Incentive Plan at the 2023-04-27 meeting.","evidence_excerpt":"Ratification and approval of the amendment to the Company’s 2017 Non-Employee Directors’ Equity Incentive Plan 132,867,426 2,097,598 16,275,102 13,664,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"64edef6a14aed61a260467faf77a74a759dc2780","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve the compensation paid to the Company’s named executive officers at the 2023-04-27 meeting.","evidence_excerpt":"Advisory vote to approve the compensation paid to the Company’s named executive officers 110,285,867 24,701,050 16,253,209","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"75c870a5626c04bf0e6926f477b673329a69de58","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the amendment to the Company’s 2017 Equity Incentive Plan at the 2023-04-27 meeting.","evidence_excerpt":"Ratification and approval of the amendment to the Company’s 2017 Equity Incentive Plan 110,232,367 24,746,403 16,261,356 13,664,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"7f7f2a7301bfa623624c072db1f94ab51cbbe1b7","claim":"LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2023 at the 2023-04-27 meeting.","evidence_excerpt":"Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2023 146,680,955 725,184 17,498,109","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000015/0001062822-23-000015-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}